Novotech Releases Report on Current State of Triple-Negative Breast Cancer Clinical Trials
Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug development landscape for Triple-Negative Breast Cancer (TNBC). The report highlights significant advancements in therapeutic strategies, regional clinical trial activity, and evolving biomarkers driving innovative TNBC treatments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113960593/en/
A Highly Aggressive Breast Cancer Subtype
TNBC, representing 10-15% of breast cancer cases worldwide, is characterized by the absence of key receptors (ER, PR, HER2), limiting the efficacy of targeted hormonal therapies. Despite advances, TNBC remains associated with poor survival rates, with metastatic cases exhibiting five-year survival of under 12%.
Global Clinical Trial Insights
From 2019 to 2024, over 1,500 clinical trials for TNBC were initiated globally, highlighting a robust commitment to improving patient outcomes. Key findings include:
- Regional Leadership: North America led TNBC trials (39%), followed closely by Asia-Pacific (33%), Europe (21%), and ROW (7%). The United States accounted for 83% of North America’s trials, while China and Australia emerged as regional leaders in Asia-Pacific.
- Biomarker-Driven Research: Novel biomarkers such as BRCA1/2 mutations, PD-L1 expression, and FGFR amplifications are increasingly targeted to drive precision therapies.
- Trial Density & Recruitment: Asia-Pacific’s lower trial density and faster recruitment rates provide unique opportunities for TNBC-focused research, supported by a large and diverse patient pool.
Innovation in Therapeutics
TNBC drug development reflects a multi-stage pipeline, with 78 Phase I, 97 Phase II, and 12 Phase III trials underway. The evolution of therapeutic strategies includes:
- Targeted Therapies: PARP inhibitors, immune checkpoint inhibitors (ICIs), and novel antibody-drug conjugates (ADCs) are transforming treatment paradigms.
- Combination Approaches: Synergistic therapies combining immunotherapy, chemotherapy, and targeted agents are enhancing efficacy.
Significant Opportunity in Asia-Pacific
The Asia-Pacific region, with its genetic diversity and unmet clinical needs, remains a focal point for TNBC trials. Novotech’s presence in key Asia-Pacific markets provides a strategic advantage in accelerating clinical research for novel TNBC therapies.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113960593/en/
Contacts
Media
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stéphane de La Faverie Announces Leadership Updates in Support of The Estée Lauder Companies’ Beauty Reimagined Vision4.2.2025 14:15:00 EET | Press release
Stéphane de La Faverie, President and CEO of The Estée Lauder Companies today announced the Company’s new organizational structure and Executive Team, to lead the Beauty Reimagined vision and action plan to be the best consumer-centric prestige beauty company in the world, and restore sales growth and stronger profitability. “Earlier today, I announced Beauty Reimagined, our bold strategic vision for the future of our incredible Company,” said Stéphane. “To deliver our action plan priorities, I am pleased to announce my new Executive Team and structure, reflecting the need to create a flatter, leaner organization and simplified operations across the business to better serve our consumers. Through a combination of elevating top talent internally and recruiting externally, we will make decisions with greater speed and agility, breaking down silos and allowing us to develop a leadership bench for the future.” This new Executive Team, who together represent decades of deep experience withi
Renowned Shark Tank investor Barbara Corcoran to Headline Kinexions 20254.2.2025 14:00:00 EET | Press release
Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced Barbara Corcoran as the celebrity keynote speaker at Kinexions 2025, its annual supply chain community conference taking place in Austin, Texas from March 31 to April 2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204938122/en/ Shark Tank investor, real estate mogul and entrepreneur Barbara Corcoran will take center stage at Kinexions 2025, the premier supply chain conference hosted by supply chain leader, Kinaxis. (Photo: Business Wire) Corcoran is the founder of The Corcoran Group, and Executive Producer and ‘shark’ on ABC’s Shark Tank, the five-time Emmy award winning show where she has invested in hundreds of businesses to date. With her innovative, outside-the-box thinking, she continues to turn Shark Tank companies into success stories every day. Corcoran will share with conference goers her leadership methodology and le
Aymium Closes $150 Million Financing With Bedrock Industries4.2.2025 14:00:00 EET | Press release
Aymium, the leading producer of renewable biocarbon products, announced today the successful completion of a five-year, $150 million financing from a wholly owned subsidiary of Bedrock Industries ManagementCo Inc. The new financing refinances Aymium’s existing debt and adds liquidity to execute the company’s near-term growth initiatives, including development of new biocarbon and biohydrogen production facilities currently under review. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204821088/en/ Aymium biocarbon production plant under construction in Williams, California, USA. (Photo: Business Wire) “We are excited to close this financing with our new partners at Bedrock Industries,” said James Mennell, CEO of Aymium. “The financing provides the company greater financial and operational flexibility, as well as significantly more liquidity which is critical to accelerate Aymium’s growth plan. Moreover, we are excited to w
Regula’s ID Verification Software Is Now Compatible with Most Passport Readers on the Market4.2.2025 14:00:00 EET | Press release
Leveraging its decades-long expertise in identity verification, Regula has made its advanced document verification software fully compatible with a wide range of third-party ID scanners and passport readers available on the market. Now, border control checkpoints, hotels, banks, medical organizations, and other institutions can take advantage of the most robust, forensic-level automated document verification and authentication regardless of the devices they are currently using. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204069695/en/ Regula’s document verification software is fully compatible with a wide range of third-party ID scanners and passport readers on the market. (Graphic: Regula) Regula’s ID verification software is an on-premises solution, which means it works offline and keeps sensitive ID data secure. It seamlessly integrates with leading passport readers and can be fully customized depending on the devic
Nymi Launches Next-Gen Wearable Authenticator For Passwordless MFA in OT Environments4.2.2025 13:00:00 EET | Press release
Nymi, Inc. today announced the launch of its next-generation wearable authenticator, the Nymi Band 4, which introduces design upgrades and expanded passwordless use cases for regulated industries, while retaining its core authentication functionality that has made it a leading solution in the life sciences manufacturing sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204711667/en/ Meet Nymi Band 4 (Photo: Business Wire) This latest development from Nymi offers industries with complex operations a handsfree solution for passwordless, Multi-Factor Authentication (MFA) that delivers strong security, compliance, and convenience for deskless workers, including manufacturing line operators, laboratory scientists, field technicians, and other critical workers in process-intensive environments. The Nymi Band 4 is available for use as a standalone FIDO2 authenticator, or as part of the Nymi Connected Worker Platform to enab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom